Research Maatschap Cardiologen Rotterdam Zuid Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2017
NCT03296540
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Research Maatschap Cardiologen Rotterdam Zuid

Active Ingredients

Drugs in Phase 4 Trials (1)

prasugrel (effient) (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiovascular Diseases (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 1